XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52-and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells

Leukemia

Volumn 26, Issue 7, 2012, Pages 1720-1722

  Rafiq, S ^a,b   Cheney, C ^b   Mo, X ^c   Jarjoura, D ^c   Muthusamy, N ^b   Byrd, J C ^b,d  

^a Integrated Biomedical Science Graduate Program   (United States)

^b Oncology and Bone Marrow Transplantation   (United States)

^c Center for Biostatistics   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BLINATUMOMAB; CD20 ANTIBODY; CD52 ANTIGEN; MONOCLONAL ANTIBODY; OFATUMUMAB; RITUXIMAB; UNCLASSIFIED DRUG; XMAB 5574;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; BLOOD CULTURE; CANCER PATIENT; CELL CULTURE; CELL FUNCTION; CROSS LINKING; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LETTER; LEUKEMIA CELL; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; MONOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL; REMISSION; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, CD20; ANTIGENS, NEOPLASM; FLOW CYTOMETRY; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, IGG;

EID: 84863784443     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.40     Document Type: Letter

References (15)

1. Xie Y, Davies SM, Xiang Y, Robison LL, Ross JA. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer 2003; 97: 2229-2235.
2. Claviez A, Eckert C, Seeger K, Schrauder A, Schrappe M, Henze G et al. Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia. Haematologica 2006; 91: 272-273.
3. Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010; 28: 3880-3889.
4. Piccaluga PP, Martinelli G, Malagola M, Rondoni M, Bonifazi F, Bandini G et al. Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. Leukemia 2005; 19: 135; author reply 136.
5. Angiolillo AL, Yu AL, Reaman G, Ingle AM, Secola R, Adamson PC. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. Pediatr Blood Cancer 2009; 53: 978-983.
6. Chevallier P, Robillard N, Houille G, Ayari S, Guillaume T, Delaunay J et al. Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases. Leukemia 2009; 23: 806-807.
7. Nijmeijer BA, van Schie ML, Halkes CJ, Griffioen M, Willemze R, Falkenburg JH. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL. Blood 2010; 116: 5930-5940.
8. Piccaluga PP, Arpinati M, Candoni A, Laterza C, Paolini S, Gazzola A et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma 2011; 52: 325-327.
9. Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 2008; 68: 8049-8057.
10. Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson Jr DM et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 2010; 115: 1204-1213.
11. Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther 2010; 335: 213-222.
12. Ward E, Mittereder N, Kuta E, Sims GP, Bowen MA, Dall'acqua W et al. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol 2011; 155: 426-437.
13. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapyrefractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29: 2493-2498.
14. Handgretinger R, Zugmaier G, Henze G, Kreyenberg H, Lang P, von Stackelberg A. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 2011; 25: 181-184.
15. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974-977.